HOME >> BIOLOGY >> NEWS
HIV-Positive Injection Drug Users Often Don't Receive Protease Inhibitors And May Not Be Aware Of The Drug

GENEVA, Switzerland--A significant number of injection drug users in San Francisco who are HIV-positive do not receive protease inhibitors and may not even be aware of these medications--despite a commitment on the part of the city to make these drugs widely available.

"We found a lot of drug users were not taking the therapies, even though they were theoretically available to them. Many had not heard of the therapies, and some of them had heard of them but were still not taking them for whatever reasons," said Brian R. Edlin, MD, of the University of California San Francisco.

In a presentation here today (July 2) at the 12th World AIDS Conference, Edlin reported findings from a UCSF study on HIV therapy availability and adherence. Lead study investigator, he is a UCSF associate professor of health policy and community medicine and director of the UCSF Urban Health Study. Edlin noted that there is a bias against providing protease inhibitors, the powerful anti-HIV medications, to injection drug users because they are perceived as being poor adherers to treatment.

Nonetheless, the city has made it a policy to provide full access to these medications to all HIV-positive individuals. Federal guidelines also recommend that practitioners not discriminate in prescribing therapy on the basis of injection drug use, he said.

The UCSF research team set out to determine if, in fact, injection drug users were receiving the therapies.

Between October 1997 and March 1998, the research team interviewed 668 injection drug users in four San Francisco neighborhoods, testing them for HIV and questioning them about their knowledge of available HIV treatments. The researchers also conducted in-depth interviews with about a dozen individuals to help understand what factors might prevent or encourage those who were HIV-positive to adhere to combination therapy.

Sixty-three of the study participants (9.4 percent) were found to be HIV-positive.
'"/>

Contact: Corinna Kaarlela
corinna@irtsa.ucsf.edu
(415) 476-3804
University of California - San Francisco
2-Jul-1998


Page: 1 2 3

Related biology news :

1. Nationwide Study Finds HIV-Positive Women Are At High Risk For Cervical Human Papillomavirus Infection
2. Injection prevents blinding blood vessel growth in mice
3. Groundwater Injection Process Filters Out Contaminants
4. Bugscope Gives Internet Users Anywhere Chance To Study Insects
5. Hopkins Study Shows Brain Damage Evidence In "Ecstasy" Users
6. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
7. HIV Patients Often Experience Viral "Breakthrough," But May Still Remain Healthy, San Francisco Study Finds
8. Research Shows That If One Identical Twin Is Prey To Nightmares, Often The Other Is Too
9. Dont always believe what you see, suggests study on false memories
10. Dont drink the water: Texas A&M researcher conducting study of polluted Mexican lake
11. Dont ban embryo-based research says new chairman of European fertility organisation

Post Your Comments:
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
(Date:5/20/2013)... planning grant will help establish the Center for Advanced ... University of Illinois at Urbana-Champaign and Worcester Polytechnic Institute ... to research in drying moist, porous materials such as ... chemical products; textiles; and biopharmaceuticals," said Hao Feng, a ... nutrition and the Illinois site director. , According to ...
(Date:5/19/2013)... a strain of electricity-producing bacteria that can grow using ... dioxide as its sole source of carbon. Researchers ... at the 113th General Meeting of the American Society ... current production solely on hydrogen," says Amit Kumar, a ... are part of the Lovley Lab Group at the ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 The Formulate ... display solution for sales and marketing teams looking for a ... describes the kit as “everything you’ll need to put together ... Display Kit comes with a number of displays and accessories ... booth 20 feet by 20 feet in size. These components ...
(Date:5/20/2013)... 20, 2013 Oven Industries Inc. announces ... capabilities. The 5R6-900 benchtop controller has many outstanding user-friendly ... be plugged into the wall as a self-contained temperature ... distinctive detail makes the device unique, as well as ... temperature controller can also be used universally, which allows ...
(Date:5/20/2013)...  Dr. Gerald Zon , noted ... launched a new blog in conjunction with TriLink BioTechnologies. ... focuses on what,s trending in the field of nucleic ... discussions of research presented at conferences and meetings, reviews ... Zon (PhD Princeton University 1971) developed automated synthesis of ...
(Date:5/20/2013)... , May 20, 2013 Cempra, ... on developing differentiated antibiotics to meet critical medical ... announced that it presented data at the American ... Philadelphia demonstrating the antibacterial and ... Cempra,s prior Phase 2 clinical trial in outpatients ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2New Laboratory Temperature Controller by Oven Industries 2Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2
Cached News: